Outpatient radiology and oncology service provider Akumin has selected Lunit’s Insight DBT breast screening software to enhance its breast imaging services.
Insight DBT is an AI-based tool that analyzes digital breast tomosynthesis (DBT) images to improve the detection of early-stage cancers while reducing false positives; it has been cleared by the U.S. Food and Drug Administration (FDA) for 3D image use.
Akumin, which operates more than 150 fixed sites as well as mobile imaging units, also provides outsourced services to more than 1,000 healthcare providers and physician groups across the U.S.
The company said that the adoption of Lunit's Insight DBT marks an important step in its plans to integrate advanced technologies that expand patient access to precision diagnostics into its network.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
